Onfekafusp Biosimilar – Anti-FN extra domain B mAb – Research Grade from ProteoGenix; catalogue PX-TA1695; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Onfekafusp Biosimilar, also known as Anti-FN extra domain B mAb, is a novel therapeutic antibody that has shown promising results in the treatment of various diseases. This biosimilar is a monoclonal antibody that specifically targets the extra domain B (EDB) of fibronectin, a protein that is overexpressed in many types of cancer and inflammatory diseases. In this article, we will discuss the structure, activity, and potential applications of Onfekafusp Biosimilar in detail.
Onfekafusp Biosimilar is a recombinant, fully humanized monoclonal antibody that is produced using advanced genetic engineering techniques. It is composed of two identical heavy chains and two identical light chains, each consisting of approximately 450 amino acids. The heavy chains are linked to the light chains by disulfide bonds, forming a Y-shaped structure. The variable regions of the antibody, responsible for binding to the target protein, are located at the tips of the Y-shaped structure.
The unique feature of Onfekafusp Biosimilar is its specificity towards the EDB domain of fibronectin. This domain is only present in the oncofetal isoform of fibronectin, which is overexpressed in cancer cells and inflammatory tissues. This allows Onfekafusp Biosimilar to selectively target and bind to these diseased cells, while sparing healthy cells.
The primary mode of action of Onfekafusp Biosimilar is through its binding to the EDB domain of fibronectin. This binding leads to the inhibition of several cellular processes that are essential for cancer growth and progression. One of the key mechanisms is the disruption of the interaction between fibronectin and its cell surface receptors, which is crucial for cancer cell survival and migration.
Moreover, Onfekafusp Biosimilar also triggers an immune response against the targeted cells. This is achieved by activating the body’s immune cells, such as natural killer cells and macrophages, to recognize and destroy the EDB-expressing cells. This dual mechanism of action makes Onfekafusp Biosimilar a potent and effective therapeutic agent for various diseases.
Onfekafusp Biosimilar has shown promising results in preclinical and clinical studies for the treatment of various types of cancer, including lung, breast, and ovarian cancer. It has also demonstrated potential in the treatment of inflammatory diseases, such as rheumatoid arthritis and psoriasis.
One of the key advantages of Onfekafusp Biosimilar is its high selectivity towards diseased cells, which minimizes the risk of side effects commonly associated with traditional cancer therapies. Additionally, its fully humanized structure reduces the risk of immunogenicity, making it a safe and well-tolerated treatment option.
Currently, Onfekafusp Biosimilar is in the early stages of development and is not yet approved for clinical use. However, with its promising results and unique mechanism of action, it has the potential to become a game-changing therapy for cancer and inflammatory diseases.
In conclusion, Onfekafusp Biosimilar is a novel therapeutic antibody that specifically targets the EDB domain of fibronectin. Its unique structure and mode of action make it a promising treatment option for various diseases, including cancer and inflammatory conditions. Further research and clinical trials are needed to fully understand the potential of Onfekafusp Biosimilar and bring it to the market for the benefit of patients.
ProteoGenix catalogue number PX-TA1695. For research use only.
Target: Onfekafusp Biosimilar – Anti-FN extra domain B mAb – Research Grade; Clonality: Monoclonal Antibody; Expression system: XtenCHO; Purity: >85%; Buffer: PBS buffer PH7.5; Applications: ELISA, WB.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA |
|---|---|---|---|---|---|---|---|---|
| Onfekafusp Biosimilar – Anti-FN extra domain B mAb – Research Grade |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
